Considering how alterations in G-proteins and/or RGS differentially affect responses to a variety of antidepressant treatments, it appears reasonable that a better understanding of these proteins could aid in the tailoring of personalized treatment strategies for depression. This evidence concerns the gene PITX2 and depressive symptom measurement.